H. Zaher, Anis A Khan, J. Palandra
Feb 6, 2006
Citations
9
Influential Citations
152
Citations
Quality indicators
Journal
The FASEB Journal
Abstract
Sulfasalazine is used in the treatment of rheumatoid arthritis, ulcerative colitis and Crohn's disease. When administered orally, sulfasalazine is poorly absorbed with an estimated bioavailability of 3–12%. Recent studies in T‐cell and Caco‐2 cell lines have shown that sulfasalazine is a substrate for the ATP‐Binding Cassette (ABC) efflux pump ABCG2. ABCG2 is known to efflux many xenobiotics and may augment the potential efficacy and toxicity of ABCG2 substrates. To date, there has not been a systematic study on the mechanisms involved in the transport of sulfasalazine, in‐vivo. We investigated whether Bcrp (abcg2) is involved in the disposition of sulfasalazine.